[go: up one dir, main page]

IS8396A - Lyfjablanda sem felur í sér P2X7 viðtakamótlyf ogbólgueyðandi lyf án stera - Google Patents

Lyfjablanda sem felur í sér P2X7 viðtakamótlyf ogbólgueyðandi lyf án stera

Info

Publication number
IS8396A
IS8396A IS8396A IS8396A IS8396A IS 8396 A IS8396 A IS 8396A IS 8396 A IS8396 A IS 8396A IS 8396 A IS8396 A IS 8396A IS 8396 A IS8396 A IS 8396A
Authority
IS
Iceland
Prior art keywords
pharmaceutical composition
receptor antagonists
steroidal anti
inflammatory drugs
inflammatory
Prior art date
Application number
IS8396A
Other languages
English (en)
Inventor
Boughton-Smith Nigel
Cruwys Simon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8396A publication Critical patent/IS8396A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS8396A 2003-09-18 2006-04-03 Lyfjablanda sem felur í sér P2X7 viðtakamótlyf ogbólgueyðandi lyf án stera IS8396A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302488A SE0302488D0 (sv) 2003-09-18 2003-09-18 New combination
PCT/SE2004/001334 WO2005025571A1 (en) 2003-09-18 2004-09-15 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug.

Publications (1)

Publication Number Publication Date
IS8396A true IS8396A (is) 2006-04-03

Family

ID=29212490

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8396A IS8396A (is) 2003-09-18 2006-04-03 Lyfjablanda sem felur í sér P2X7 viðtakamótlyf ogbólgueyðandi lyf án stera

Country Status (20)

Country Link
US (1) US20070082930A1 (is)
EP (1) EP1663224A1 (is)
JP (1) JP2007505900A (is)
KR (1) KR20060086942A (is)
CN (1) CN1859911A (is)
AR (1) AR045783A1 (is)
AU (1) AU2004271886B2 (is)
BR (1) BRPI0414558A (is)
CA (1) CA2538416A1 (is)
IL (1) IL173913A0 (is)
IS (1) IS8396A (is)
MX (1) MXPA06002722A (is)
NO (1) NO20061662L (is)
NZ (1) NZ545964A (is)
RU (1) RU2338556C2 (is)
SE (1) SE0302488D0 (is)
TW (1) TW200526199A (is)
UY (1) UY28517A1 (is)
WO (1) WO2005025571A1 (is)
ZA (1) ZA200602260B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
TW200507829A (en) * 2003-05-29 2005-03-01 Astrazeneca Ab New combination
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
WO2007098086A2 (en) * 2006-02-17 2007-08-30 Avalon Pharmaceuticals Hydroxypiperidine derivatives and uses thereof
GB0724258D0 (en) * 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
WO2009074518A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
CN104623665B (zh) * 2009-12-08 2018-01-12 范德比尔特大学 用于静脉采集和自体移植的改进的方法和组合物
EA201290876A1 (ru) 2010-03-05 2013-03-29 Президент Энд Феллоуз Оф Гарвард Колледж Композиции индуцированных дендритных клеток и их использование
WO2013082565A1 (en) * 2011-12-02 2013-06-06 Michael Kaleko Therapies for disorders of the cornea and conjunctiva
CN111904926B (zh) * 2014-09-10 2023-10-10 Gsk消费者健康有限责任公司 局部用双氯芬酸钠组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
DE69738949D1 (de) * 1996-05-20 2008-10-09 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CA2368829A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SK9022002A3 (en) * 1999-12-22 2003-03-04 Pharmacia Corp Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
JP4523273B2 (ja) * 2001-07-02 2010-08-11 ナームローゼ・フエンノートチヤツプ・オルガノン テトラヒドロキノリン誘導体
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
TW200507829A (en) * 2003-05-29 2005-03-01 Astrazeneca Ab New combination
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
AU2004271886B2 (en) 2008-03-20
UY28517A1 (es) 2005-04-29
EP1663224A1 (en) 2006-06-07
IL173913A0 (en) 2006-07-05
SE0302488D0 (sv) 2003-09-18
BRPI0414558A (pt) 2006-11-07
KR20060086942A (ko) 2006-08-01
TW200526199A (en) 2005-08-16
RU2338556C2 (ru) 2008-11-20
ZA200602260B (en) 2007-07-25
WO2005025571A1 (en) 2005-03-24
CN1859911A (zh) 2006-11-08
NO20061662L (no) 2006-04-11
US20070082930A1 (en) 2007-04-12
CA2538416A1 (en) 2005-03-24
NZ545964A (en) 2009-09-25
MXPA06002722A (es) 2006-06-06
AR045783A1 (es) 2005-11-16
RU2006112423A (ru) 2007-11-10
AU2004271886A1 (en) 2005-03-24
JP2007505900A (ja) 2007-03-15

Similar Documents

Publication Publication Date Title
IS8396A (is) Lyfjablanda sem felur í sér P2X7 viðtakamótlyf ogbólgueyðandi lyf án stera
NO20042905L (no) Farmasoytisk nanopartikkelpreparat av en takykinin reseptor antagonist
IL166286A0 (en) Multicomponent pharmaceutical dosage form
ATE282428T1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
ATE407125T1 (de) Pharmazeutische zusammenstellungen aus tachykinin antagonisten und einen serotonin-wiederaufname hemmer
EP1528066A4 (en) ARYL-t-THIO-B-GLUCOPYRANOSIDE DERIVATIVES AND DIABETES CONTAINING THEM
IS8353A (is) Lyfjablanda sem felur í sér lantanefnasambönd
DE122011100047I1 (de) Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol.
NO20020464L (no) Flerkomponents farmasöytisk doseringsform
ATE380544T1 (de) Umhüllte feste darreichungsform
IS2946B (is) Lyfjablanda sem felur í sér andrógen
ATE394375T1 (de) Zusammensetzung enthaltend einen tachykininrezeptor antagonisten und einen serotonin-wiederaufnahmehemmer
IS8188A (is) Lyfjablanda sem felur í sér P2X7 viðtakamótlyf ogæxlisdrepboða a
DE60329755D1 (de) Basische nichtpeptid-bradykinin-antagonisten und pharmazeutische zusammensetzungen daraus
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
DE60029340D1 (de) Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran
IL142037A0 (en) Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
EP1737471A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SILICON-SUBSTITUTED CYCLO-OXYGENASE-2 LIPOPHILIC DRUGS AND DERIVATIVES
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
ITMI20041963A1 (it) "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
DK200300348U4 (da) Fast farmaceutisk dosisform omfattende amlodipinmaleat
ATE332690T1 (de) Perindopril enthaltende pharmazeutische zusammensetzung mit oraler dispersion
IL175827A0 (en) Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability
DK1750765T3 (da) Farmaceutisk antimykobakteriesammensætning omfattende et antituberkulöst lægemiddel
ATE327758T1 (de) In der mundhöhle dispergierbare pharmazeutische zusammensetzung mit piribedil